Thursday, April 18, 2024
HomeFunding Cambridge-based Ceretype Neuromedicine Secures its Second Round of Seed Funding

[Funding alert] Cambridge-based Ceretype Neuromedicine Secures its Second Round of Seed Funding

Cambridge-based Ceretype Neuromedicine secures its second round of seed funding. The company’s $2MM funding target was oversubscribed.

Cambridge-based Ceretype Neuromedicine secures its second round of seed funding. The company’s $2MM funding target was oversubscribed.

The round was led by Cedar Street Group, LLC, an early-stage venture and seed financing fund based in Westchester, NY. Other participants include Leafy Tunnel, The One Mind Accelerator and several private investors.

Read also – CA-based Hyperlink Ventures Secures it’s First fund at $32M

Cedar Street Group Managing Principal Paul Francis said, “We are pleased to support Ceretype and help accelerate their mission to make targeted biomarkers accessible in psychiatric and neurological disease. Ceretype’s proprietary end-to-end platform brings remarkable innovation to the previous shortcomings of traditional fMRI, unlocking a powerful tool to visualize and study brain circuitry at a scale that has not been possible before,”.

Ceretype was founded in 2020 by experts in neuromedicine and brain imaging to translate years of academic research into practical tools that will transform therapeutic development and clinical care. Since its founding, Ceretype has partnered with several pharmaceutical and biotech companies to help visualize and quantitatively analyze the impact of their treatments on the functional networks within patients’ brains.

Read also – ME-based Biochar Producer Standard Biocarbon Secures $5M in Funding

Ceretype’s Co-Founder & CEO Emily Stern, MD said, “We are grateful for our investors’ continued support and excitement around our groundbreaking fMRI platform. This investment will allow us to continue to make fMRI more accessible, and to deliver actionable evidence to improve drug discovery and, ultimately, patient care,”.

About Ceretype Neuromedicine

Ceretype has pioneered the practical application & integration of fMRI in neuropsychiatric drug development and beyond. Their uniquely scalable end-to-end platform makes targeted biomarkers accessible, delivering actionable evidence to improve drug discovery and, ultimately, patient care.

 Read also – CA-based Vasa Therapeutics Secures a Seed Funding

- Advertisement -
RELATED ARTICLES
- Advertisment -

Most Popular